Related Experiment Videos
Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure
Alberto Palazzuoli1, Ilaria Quatrini, Lucia Vecchiato
1Department of Internal Medicine and Metabolic Diseases, Section of Cardiology, University of Siena, Siena, Italy. palazzuoli2@unisi.it
Journal of Cardiovascular Pharmacology
|May 18, 2005
Summary
Carvedilol significantly improves diastolic function in chronic heart failure patients, converting restrictive filling patterns to altered patterns. These benefits persist long-term, alongside improved systolic function and reduced pulmonary pressure.
Area of Science:
- Cardiology
- Pharmacology
- Echocardiography
Background:
- Carvedilol reduces mortality in chronic heart failure (CHF) by enhancing systolic function and mitigating left ventricular remodeling.
- The impact of carvedilol on left ventricular (LV) filling patterns in advanced CHF remains less understood.
Purpose of the Study:
- To evaluate early and long-term diastolic cardiac modifications induced by carvedilol therapy in advanced CHF patients.
- To assess changes in LV filling patterns, specifically in patients with pseudonormal or restrictive filling.
Main Methods:
- A randomized study involving 58 severe CHF patients (NYHA class III/IV) with systolic and diastolic dysfunction.
- Thirty-two patients received carvedilol plus standard therapy (group 1), while 26 received standard therapy alone (group 2).
- Echocardiography assessed LV volumes, mass, ejection fraction (EF), and transmitral filling parameters (E, A waves, E/A ratio, DT, IVRT) at baseline, 4 months, and 12 months.
Main Results:
- After 4 months, the carvedilol group showed significant increases in A wave, deceleration time (DT), and isovolumetric relaxation time (IVRT), with a reduced E/A ratio compared to controls.
- Improvements in A wave, DT, IVRT, and E/A ratio were sustained and further enhanced at 12 months, with a notable reduction in E wave.
- At 1 year, the carvedilol group exhibited reduced LV systolic volume, decreased pulmonary pressure, and increased EF.
Conclusions:
- Carvedilol effectively improves diastolic function in CHF patients with severe systolic and diastolic impairment, transitioning restrictive/pseudonormal patterns to altered patterns.
- These diastolic improvements are sustained for at least 1 year, accompanied by significant enhancements in systolic function and hemodynamic parameters.